These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 31316010)

  • 1. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment.
    Zemek RM; De Jong E; Chin WL; Schuster IS; Fear VS; Casey TH; Forbes C; Dart SJ; Leslie C; Zaitouny A; Small M; Boon L; Forrest ARR; Muiri DO; Degli-Esposti MA; Millward MJ; Nowak AK; Lassmann T; Bosco A; Lake RA; Lesterhuis WJ
    Sci Transl Med; 2019 Jul; 11(501):. PubMed ID: 31316010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade.
    Wang C; Cui A; Bukenya M; Aung A; Pradhan D; Whittaker CA; Agarwal Y; Thomas A; Liang S; Amlashi P; Suh H; Spranger S; Hacohen N; Irvine DJ
    Cell Rep; 2021 Nov; 37(8):110021. PubMed ID: 34818534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
    Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
    JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer/testis Antigen MAGEA3 Interacts with STAT1 and Remodels the Tumor Microenvironment.
    Wang Y; Song X; Zheng Y; Liu Z; Li Y; Qian X; Pang X; Zhang Y; Yin Y
    Int J Med Sci; 2018; 15(14):1702-1712. PubMed ID: 30588194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade.
    Sato Y; Bolzenius JK; Eteleeb AM; Su X; Maher CA; Sehn JK; Arora VK
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.
    Gao X; Wang X; Yang Q; Zhao X; Wen W; Li G; Lu J; Qin W; Qi Y; Xie F; Jiang J; Wu C; Zhang X; Chen X; Turnquist H; Zhu Y; Lu B
    J Immunol; 2015 Jan; 194(1):438-45. PubMed ID: 25429071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling.
    Raja R; Wu C; Bassoy EY; Rubino TE; Utagawa EC; Magtibay PM; Butler KA; Curtis M
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36564125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-32γ potentiates tumor immunity in melanoma.
    Gruber T; Kremenovic M; Sadozai H; Rombini N; Baeriswyl L; Maibach F; Modlin RL; Gilliet M; von Werdt D; Hunger RE; Seyed Jafari SM; Parisi G; Abril-Rodriguez G; Ribas A; Schenk M
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32841222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis.
    Neo SY; Tong L; Chong J; Liu Y; Jing X; Oliveira MMS; Chen Y; Chen Z; Lee K; Burduli N; Chen X; Gao J; Ma R; Lim JP; Huo J; Xu S; Alici E; Wickström SL; Haglund F; Hartman J; Wagner AK; Cao Y; Kiessling R; Lam KP; Westerberg LS; Lundqvist A
    Sci Transl Med; 2024 May; 16(747):eadi2952. PubMed ID: 38748775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
    Zhang C; Liu Y
    Front Immunol; 2020; 11():1295. PubMed ID: 32714324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade.
    Chen IX; Newcomer K; Pauken KE; Juneja VR; Naxerova K; Wu MW; Pinter M; Sen DR; Singer M; Sharpe AH; Jain RK
    Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23684-23694. PubMed ID: 32907939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer group 2D receptor and its ligands in cancer immune escape.
    Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
    Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations.
    Principe N; Aston WJ; Hope DE; Tilsed CM; Fisher SA; Boon L; Dick IM; Chin WL; McDonnell AM; Nowak AK; Lake RA; Chee J; Lesterhuis WJ
    Front Immunol; 2022; 13():872295. PubMed ID: 35634282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4
    Doorduijn EM; Sluijter M; Salvatori DC; Silvestri S; Maas S; Arens R; Ossendorp F; van der Burg SH; van Hall T
    Cancer Immunol Res; 2017 Aug; 5(8):642-653. PubMed ID: 28637878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-146a Controls Immune Response in the Melanoma Microenvironment.
    Mastroianni J; Stickel N; Andrlova H; Hanke K; Melchinger W; Duquesne S; Schmidt D; Falk M; Andrieux G; Pfeifer D; Dierbach H; Schmitt-Graeff A; Meiss F; Boerries M; Zeiser R
    Cancer Res; 2019 Jan; 79(1):183-195. PubMed ID: 30425059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STAT1 as a tool for non-invasive monitoring of NK cell activation in cancer.
    Min JY; Kim HM; Lee H; Cho MY; Park HS; Lee SY; Park MS; Ha SK; Kim D; Jeong HG; Kim TD; Hong KS; Han EH
    Commun Biol; 2024 Sep; 7(1):1222. PubMed ID: 39349746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells.
    Quatrini L; Vacca P; Tumino N; Besi F; Di Pace AL; Scordamaglia F; Martini S; Munari E; Mingari MC; Ugolini S; Moretta L
    J Allergy Clin Immunol; 2021 Jan; 147(1):349-360. PubMed ID: 32417134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonal tracing reveals diverse patterns of response to immune checkpoint blockade.
    Gu SS; Wang X; Hu X; Jiang P; Li Z; Traugh N; Bu X; Tang Q; Wang C; Zeng Z; Fu J; Meyer C; Zhang Y; Cejas P; Lim K; Wang J; Zhang W; Tokheim C; Sahu AD; Xing X; Kroger B; Ouyang Z; Long H; Freeman GJ; Brown M; Liu XS
    Genome Biol; 2020 Oct; 21(1):263. PubMed ID: 33059736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.